文献速递胰腺与胆道疾病消化道肿瘤与早癌消化内镜

不可切除恶性胆道梗阻的照射支架与常规金属支架对比:一项多中心试验

Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: A multicenter trial.
PubMed 文献 · J Hepatol · 2018-01-10

本多中心随机开放标签试验在中国20个中心纳入328例不可切除恶性胆道梗阻患者,平行分组比较照射支架与无覆膜自膨式金属支架。照射支架组支架通畅时间第一四分位数212天 vs 无覆膜支架组104天,90、180、360天再狭窄率更低(p=0.010),中位生存202天 vs 140天(p=0.020);技术成功率、黄疸缓解及3-4级并发症发生率无显著差异。

要点

  • 照射支架组支架通畅时间第一四分位数为212天,无覆膜自膨式金属支架组为104天。
  • 照射支架组再狭窄率90天9% vs 15%、180天16% vs 27%、360天21% vs 33%,p=0.010。
  • 照射支架组中位生存202天 vs 无覆膜支架组140天,p=0.020。

核心结论

  • 置入照射支架而非无覆膜自膨式金属支架可改善不可切除恶性胆道梗阻患者的支架通畅性和总生存。

研究设计与样本

  • 随机、开放标签试验,在中国20个中心纳入328例不可切除恶性胆道梗阻参与者,平行分配至照射支架组(ISG)或无覆膜自膨式金属支架组(USG)。

主要发现

  • 支架通畅时间第一四分位数(25%患者发生支架再狭窄时)照射支架组为212天,无覆膜支架组为104天。
  • 照射支架与支架再狭窄率降低显著相关:90天9% vs 15%,180天16% vs 27%,360天21% vs 33%,p=0.010。
  • 照射支架组生存时间更长:中位202天 vs 140天,p=0.020。
  • 技术成功率93% vs 95%(p=0.499)、黄疸缓解85% vs 80%(p=0.308)、3级和4级并发症发生率8.5% vs 7.9%(p=0.841)均无显著差异。

临床怎么用

  • 对于不可切除恶性胆道梗阻患者,置入自膨式金属支架是推荐的姑息性方式,用以缓解瘙痒、胆管炎、疼痛和黄疸。
  • 作者结论认为,置入照射支架而非无覆膜自膨式金属支架可改善不可切除恶性胆道梗阻患者的支架通畅性和总生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Placement of an irradiation stent has been demonstrated to offer longer patency and survival than an uncovered self-expandable metallic stent (SEMS) in patients with unresectable malignant biliary obstruction (MBO). We aim to further assess the efficacy of an irradiation stent compared to an uncovered SEMS in those patients. METHODS: We performed a randomized, open-label trial of participants with unresectable MBO at 20 centers in China. A total of 328 participants were allocated in parallel to the irradiation stent group (ISG) or the uncovered SEMS group (USG). Endpoints included stent patency (primary), technical success, relief of jaundice, overall survival, and complications. RESULTS: The first quartile stent patency time (when 25% of the patients experienced stent restenosis) was 212 days for the ISG and 104 days for the USG. Irradiation stents were significantly associated with a decrease in the rate of stent restenosis (9% vs. 15% at 90 days; 16% vs. 27% at 180 days; 21% vs. 33% at 360 days; p = 0.010). Patients in the ISG obtained longer survival time (median 202 days vs. 140 days; p = 0.020). No significant results were observed in technical success rate (93% vs. 95%; p = 0.499), relief of jaundice (85% vs. 80%; p = 0.308), and the incidence of grade 3 and 4 complications (8.5% vs. 7.9%; p = 0.841). CONCLUSIONS: Insertion of irradiation stents instead of uncovered SEMS could improve patency and overall survival in patients with unresectable MBO. LAY SUMMARY: For patients with unresectable malignant biliary obstruction (MBO), placement of a self-expandable metallic stent (SEMS) is a recommended palliative modality to relieve pruritus, cholangitis, pain, and jaundice. However, restenosis is a main pitfall after stent placement. Data from this first multicenter randomized controlled trial showed that insertion of an irradiation stent provided longer patency and better survival than a conventional metal stent. ClinicalTrials.gov ID: NCT02001779.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Zhu HD, Guo JH, Huang M, et al. Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: A multicenter trial. J Hepatol. 2018. PMID: 29331343. doi:10.1016/j.jhep.2017.12.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。